These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18785126)

  • 41. Serum analysis of coagulation factors in IPF and NSIP.
    Bargagli E; Madioni C; Bianchi N; Refini RM; Cappelli R; Rottoli P
    Inflammation; 2014 Feb; 37(1):10-6. PubMed ID: 23912648
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased level of soluble E-selectin in the serum from patients with idiopathic pulmonary fibrosis.
    Hayashi S; Abe K; Matsuoka H; Goya S; Morishita H; Mori M; Arai T; Kida H; Nishino K; Takeda Y; Osaki T; Tachibana I; Kimura K; Yokota S; Inoue Y; Sakatani M
    Inflammation; 2004 Feb; 28(1):1-5. PubMed ID: 15072224
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Protein S and protein C anticoagulant activity in acute and chronic cardiac ischemic syndromes. Relationship to inflammation, complement activation and in vivo thrombin activity.
    D'Angelo A; Gerosa S; D'Angelo SV; Mailhac A; Colombo A; Agazzi A; Mazzola G; Chierchia S
    Thromb Res; 1994 Jul; 75(2):133-42. PubMed ID: 7974387
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased thrombogenesity in patients with cyanotic congenital heart disease.
    Kajimoto H; Nakazawa M; Murasaki K; Mori Y; Tanoue K; Kasanuki H; Nakanishi T
    Circ J; 2007 Jun; 71(6):948-53. PubMed ID: 17526995
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bariatric surgery in morbidly obese individuals affects plasma levels of protein C and thrombomodulin.
    Rega-Kaun G; Kaun C; Ebenbauer B; Jaegersberger G; Prager M; Wojta J; Hohensinner PJ
    J Thromb Thrombolysis; 2019 Jan; 47(1):51-56. PubMed ID: 30259314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased plasma soluble thrombomodulin levels as a risk factor for pulmonary thromboembolism.
    Yin YD; Wang C; Zhai ZG; Pang BS; Yang YH; Huang XX
    J Thromb Thrombolysis; 2009 Apr; 27(3):274-9. PubMed ID: 18373234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Decreased Activity of the Protein C Anticoagulant Pathway in the Early Hours of Paroxysmal Atrial Fibrillation.
    Negreva M; Georgiev S; Vitlianova K
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):793-799. PubMed ID: 27313201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potential role of endothelin-1 in pulmonary fibrosis: from the bench to the clinic.
    Barlo NP; van Moorsel CH; Kazemier KM; van den Bosch JM; Grutters JC
    Am J Respir Cell Mol Biol; 2010 May; 42(5):633. PubMed ID: 20393073
    [No Abstract]   [Full Text] [Related]  

  • 49. Biological variation in protein C, protein S and antithrombin concentrations in plasma of healthy subjects.
    Melzi d'Eril G; Anesi A; Rizzo V; Trotti R
    Eur J Clin Chem Clin Biochem; 1997 Apr; 35(4):257-60. PubMed ID: 9166965
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Detection of anti-periplakin auto-antibodies during idiopathic pulmonary fibrosis.
    Mignot S; Taille C; Besnard V; Crestani B; Chollet-Martin S
    Clin Chim Acta; 2014 Jun; 433():242. PubMed ID: 24685571
    [No Abstract]   [Full Text] [Related]  

  • 51. Too Premature to Deny the Potential of Thrombomodulin Alfa in Idiopathic Pulmonary Fibrosis.
    Kobayashi T; Hataji O; Fujimoto H; D'Alessandro-Gabazza C; Yasuma T; Gabazza EC
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1449-1450. PubMed ID: 32150439
    [No Abstract]   [Full Text] [Related]  

  • 52. Reply to Horita and Takeshi: Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.
    Kondoh Y; Azuma A; Tagawa J; Homma S
    Am J Respir Crit Care Med; 2020 Jul; 202(1):151-152. PubMed ID: 32228231
    [No Abstract]   [Full Text] [Related]  

  • 53. Thrombomodulin Did Not Benefit Acute Exacerbation of Idiopathic Pulmonary Fibrosis in a Trial.
    Horita N; Takeshi K
    Am J Respir Crit Care Med; 2020 Jul; 202(1):150-151. PubMed ID: 32228230
    [No Abstract]   [Full Text] [Related]  

  • 54. Risk prediction in idiopathic pulmonary fibrosis.
    Ley B; Collard HR
    Am J Respir Crit Care Med; 2012 Jan; 185(1):6-7. PubMed ID: 22210784
    [No Abstract]   [Full Text] [Related]  

  • 55. Disease stratification in idiopathic pulmonary fibrosis: the dawn of a new era?
    Maher TM
    Eur Respir J; 2014 May; 43(5):1233-6. PubMed ID: 24789946
    [No Abstract]   [Full Text] [Related]  

  • 56. Reply to Kobayashi
    Kondoh Y; Azuma A; Tagawa J; Yamamori N; Homma S
    Am J Respir Crit Care Med; 2020 Jun; 201(11):1450-1451. PubMed ID: 32150449
    [No Abstract]   [Full Text] [Related]  

  • 57. Biomarkers in idiopathic pulmonary fibrosis: picking the winners for trials.
    Crooks MG; Hart SP
    Lancet Respir Med; 2015 Jun; 3(6):421-2. PubMed ID: 25770675
    [No Abstract]   [Full Text] [Related]  

  • 58. [Update on idiopathic pulmonary fibrosis. Introduction].
    Xaubet A; Ancochea J
    Arch Bronconeumol; 2012 Oct; 48 Suppl 2():1. PubMed ID: 23116900
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms.
    Kreuter M; Maher TM
    Am J Respir Crit Care Med; 2020 May; 201(9):1030-1032. PubMed ID: 31978310
    [No Abstract]   [Full Text] [Related]  

  • 60. Fibrocytes as potential biomarkers in idiopathic pulmonary fibrosis.
    Moore BB
    Am J Respir Crit Care Med; 2009 Apr; 179(7):524-5. PubMed ID: 19318541
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.